Alx Oncology Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>AO</div>
ALXO -- USA Stock  

USD 80.96  0.48  0.59%

A current spike in volatility has left many institutional investors looking confused. In this story, we will outline Alx Oncology Holdings. We will evaluate if Alx Oncology shares are reasonably priced going into January. Alx Oncology Holdings is presently traded for 112.26. The entity has historical hype elasticity of -4.0. The average price elasticity to hype of competition is about 0.27. The firm is forecasted to decline in value after the next press release, with the price expected to drop to 108.26. The average volatility of headline impact on the company stock price is huge, making predictions on the news or social media along less reliable. The price decrease on the next news is expected to be -3.56%, whereas the daily expected return is presently at 1.86 percent. Given the investment horizon of 30 days the next forecasted announcement will be very soon.
Published over a month ago
View all stories for Alx Oncology | View All Stories
Thinking to buy more of Alx Oncology (NASDAQ:ALXO)?
Alx Oncology holds a performance score of 19 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.0595, which signifies not very significant fluctuations relative to the market. Let's try to break down what Alx Oncology's beta means in this case. As returns on the market increase, returns on owning Alx Oncology are expected to decrease at a much lower rate. During the bear market, Alx Oncology is likely to outperform the market. Although it is essential to pay attention to Alx Oncology Holdings historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Alx Oncology Holdings expected return of 1.86 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Alx Oncology potential upside, as well as the relationship between the kurtosis and day typical price to analyze future returns on Alx Oncology.
The successful prediction of Alx Oncology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Alx Oncology Holdings, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Alx Oncology based on Alx Oncology hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Alx Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Alx Oncology's related companies.

Use Technical Analysis to project Alx Oncology expected Price

Alx Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Alx Oncology technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Alx Oncology trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Alx Oncology utilizes its cash?

To perform a cash flow analysis of Alx Oncology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Alx Oncology is receiving and how much cash it distributes out in a given period. The Alx Oncology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Alx Oncology Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (13.84 Million)

Alx Oncology exotic insider transaction detected

Legal trades by Alx Oncology insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Alx Oncology insider trading alert for general transaction of common stock by Graham G Walmsley, the corporate stakeholder, on 15th of December 2020. This event was filed by Alx Oncology Holdings Inc with SEC on 2020-12-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at Alx Oncology

The latest price rise of Alx Oncology Holdings could raise concerns from institutional investors as the firm it trading at a share price of 112.26 on 1,041,600 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in January. The stock standard deviation of daily returns for 30 days investing horizon is currently 6.89. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Alx Oncology partners.

Cost of Revenue Breakdown

Alx Oncology Cost of Revenue yearly trend continues to be quite stable with very little volatility. The value of Cost of Revenue is projected to decrease to about 4.1 M. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Alx Oncology Cost of Revenue is quite stable at the moment as compared to the past year. The company's current value of Cost of Revenue is estimated at 4.1 Million
20101.88 Million
20194.36 Million
20204.1 Million

Will Alx Oncology growth be justifiable after the rise?

Latest semi deviation is at 3.29. Alx Oncology Holdings shows above-average downside volatility for the selected time horizon. We advise investors to inspect Alx Oncology Holdings further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Alx Oncology future alpha.

Whereas other companies under the biotechnology industry are still a bit expensive, Alx Oncology may offer a potential longer-term growth to institutional investors. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to drop some or all of your Alx Oncology holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Alx Oncology.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Alx Oncology Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to